DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20184317

Evaluation of the protective effect of Paeonia emodi Wall on rat model of Parkinson’s disease induced by 6 hydroxy dopamine

Sharmila V. Jalgaonkar, Abhay P. Kamble, Urwashi I. Parmar, Dnyaneshwar G. Kurle, Moin S. Bedrekar, Malvika Gursahani

Abstract


Background: Generation of reactive oxygen species together with paucity of antioxidant defense is considered as an important cause for dopaminergic neuronal death. Review of literature indicates that none of the drugs so far studied for preventing the PD were found to be promising for use. Therefore, the present study was planned to evaluate the neuroprotective effect of Paeonia emodi Wall (PEW) in 6-hydroxy dopamine induced Parkinson’s disease (PD) model.

Methods: The study was conducted on Wistar rats where Parkinson’s disease was induced by producing the striatal 6-hydroxy dopamine lesions. The test animals received ethanolic extract of PEW at dose of 200 and 300mg/kg for 28 days. Circling behavior, spontaneous locomotor activity, muscular coordination and akinesia were studied. Antioxidant levels were assessed by biochemical estimation and histopathology was carried out for dopaminergic neuronal loss.

Results: PEW ethanolic extract showed significant dose dependent recovery in number of circlings, line crossing, muscular coordination and akinesia. A significant increase in MDA levels and decreased GSH level in PEW treated groups was observed in test groups as compared to control group (p<0.05). Normal architecture was retained only in PEW 300mg/Kg (p<0.05). L-Dopa did not showed effect on biochemical and histological parameters.

Conclusions: The ethanolic extract of PEW showed neuroprotective activity against 6-hydroxy dopamine induced Parkinson’s disease in rats in both 200 and 300mg/kg doses. The protective action of PEW in PD can be because of its ability to reduce the oxidative stress.


Keywords


Biochemical, Histopathological, Oxidative stress, Paeonia Emodi Wall, Stepping test, Stereotaxic, 6-Hydroxydopamine

Full Text:

PDF

References


Olanow CW SA. Parkinson’s Disease and Other Movement Disorders. In: Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J (eds.). In: Harrison’s principles of internal medicine. 18th ed. USA: Mc Graw Hill; 2012. p. 3327.

Crotty GF, Ascherio A, Schwarzschild MA. Targeting urate to reduce oxidative stress in Parkinson disease. Exp Neurol. Elsevier Inc; 2017;298:210–24.

Tysnes OB, Storstein A. Epidemiology of Parkinson’s disease. J Neural Transm. Springer Vienna; 2017;124(8):901–5.

Muthane UB, Ragothaman M, Gururaj G. Epidemiology of Parkinson’s Disease and Movement Disorders in India : Problems and Possibilities. October. 2007;55(October):14–6.

Essa MM, Vijayan RK, Castellano-Gonzalez G, Memon MA, Braidy N, Guillemin GJ. Neuroprotective effect of natural products against Alzheimer’s disease. Neurochem Res. 2012;37(9):1829–42.

Zargar BA, Masoodi MH, Khan BA, Akbar S. Paeonia emodi Royle: Ethnomedicinal uses, phytochemistry and pharmacology. Phytochem Lett. Phytochemical Society of Europe; 2013;6(2):261–6.

Taous Khan, Mansoor Ahmad HK and MAK. Biological activities of aerial parts of Paeonia emodi. African J Biotechnol. 2005;4(November):1313–6.

Singh BP, Deepa. Critical analysis of kampavata (parkinsonism). Int Ayurvedic J. 2015;3(6):1767–73.

Zargar BA, Masoodi MH, Ahmed B, Ganie SA. Antihyperlipidemic and Antioxidant Potential of Paeonia emodi Royle against High-Fat Diet Induced Oxidative Stress. ISRN Pharmacol. 2014;2014:182362.

Blesa J, Phani S, Jackson-Lewis V, Przedborski S. Classic and new animal models of Parkinson’s disease. J Biomed Biotechnol. 2012;2012.

Kirby ED, Jensen K, Goosens KA, Kaufer D. Stereotaxic surgery for excitotoxic lesion of specific brain areas in the adult rat. J Vis Exp. 2012;(65):e4079.

Agrawal SS, Gullaiya S, Dubey V, Singh V, Kumar A, Nagar A, et al. Neurodegenerative shielding by curcumin and its derivatives on brain lesions induced by 6-OHDA model of Parkinson’s disease in albino wistar rats. Cardiovasc Psychiatry Neurol. 2012;2012:8.

Shalavadi MH, Chandrashekhar VM, Avinash SP, Sowmya C, Ramkishan A. Neuroprotective activity of Stereospermum suaveolens DC against 6-OHDA induced Parkinson ’ s disease model. indian J Pharmacol. 2012;44(6):737–43.

Campbell JC, Jeyamohan SB, Cruz PD La, Chen N, Shin D, Pilitsis JG. Place conditioning to apomorphine in rat models of Parkinson’s disease: Differences by dose and side-effect expression. Behav Brain Res. Elsevier B.V.; 2014;275:114–9.

Konieczny J, Czarnecka A, Lenda T, Kamińska K, Antkiewicz-Michaluk L. The significance of rotational behavior and sensitivity of striatal dopamine receptors in hemiparkinsonian rats: A comparative study of lactacystin and 6-OHDA. Neuroscience. 2017;340:308–18.

Chen XY, Li J, Qi WQ, Shen SH. Experimental change on dopaminergic neurons in striatum of Parkinson disease rats. 2007;1085–90.

Ellis JM, Fell MJ. Current approaches to the treatment of Parkinson’s Disease. Bioorg Med Chem Lett. 2017;27:4247–55.

Pathak- Gandhi N, Vaidya ADB. Management of Parkinson’s disease in Ayurveda: Medicinal plants and adjuvant measures. J Ethnopharmacol. 2017;197:46–51.

Uddin G, Sadat A, Siddiqui BS. Phytochemical Screening , In vitro Antioxidant and Antimicrobial Activities of the Crude Fractions of Paeonia emodi Wall . Ex Royle. 2013;17(3):367–73.

S.M. Abbas Zaidi. et al. P emodia epilepsy India root.pdf. New Delhi: Journal of Pharmacolody and Toxicology; 2012. p. 64–77.

Sharma P.V. Dravyaguna-Vidnyana. 2nd ed. Chaukhana Bharati Academy; 2001. 86 p.

Duty S, Jenner P. Animal models of Parkinson’s disease: A source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 2011;164(4):1357–91.

Zhang K, Jiayu G, Zaijun Z. Evaluation of Parkinson’s disease in 3 rat models induced by three different unilateral injections of. J Pharm Biomed Sci. 2015;5(11):842–7.

Simola N, Morelli M, Carta AR. The 6-hydroxydopamine model of Parkinson’s disease. Neurotox Res. 2007;11(3–4):151–67.

Carvalho MM, Campos FL, Coimbra B, Pêgo JM, Rodrigues C, Lima R, et al. Behavioral characterization of the 6-hydroxidopamine model of Parkinson’s disease and pharmacological rescuing of non-motor deficits. Mol Neurodegener. 2013;8(1):14.

Blandini F, Armentero M-T. Animal models of Parkinson’s disease. FEBS J. 2012;279(7):1156–66.

Singh S, Ahmed R, Sagar RK, Krishana B. Neuroprotection of the nigrostriatal dopaminergic neurons by melatonin in hemiparkinsonium rat. Indian J Med Res. 2006;124(OCT.):419–26.

Antala B V, Patel MS, Bhuva S V, Gupta S. Protective effect of methanolic extract of Garcinia indica fruits in 6-OHDA rat model of Parkinson ’ s disease. 2012;44(6):683–7.

Olsson M, Nikkhah G. Forelimb Akinesia in the Rat Parkinson Model : Differential Effects of Dopamine Agonists and Nigral Transplants as Assessed by a New Stepping Test. J Neurosci. 1995;15(5):3863–75.

A KS, Vijayalakshmi K, Nagappan P, Balima S. Effect of sesamol in association with folic acid on 6-ohda induced parkinsonian animals-biochemical , neurochemical and histopathological evidence. Asian J Pharm Clin Res. 2017;10(4):6–10.